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De Novo Mutations in YWHAG Cause Early-Onset Epilepsy
Ilaria Guella,1,9 Marna B. McKenzie,1,9 Daniel M. Evans,1 Sarah E. Buerki,2 Eric B. Toyota,3
Margot I. Van Allen,4 Epilepsy Genomics Study, Mohnish Suri,5 Frances Elmslie,6 Deciphering
Developmental Disorders Study, Marleen E.H. Simon,7 Koen L.I. van Gassen,7 Delphine He´ron,8
Boris Keren,8 Caroline Nava,8 Mary B. Connolly,3 Michelle Demos,3,* and Matthew J. Farrer1,*
Massively parallel sequencing has revealed many de novo mutations in the etiology of developmental and epileptic encephalopathies
(EEs), highlighting their genetic heterogeneity. Additional candidate genes have been prioritized in silico by their co-expression in the
brain. Here, we evaluate rare coding variability in 20 candidates nominated with the use of a reference gene set of 51 established EE-asso-
ciated genes. Variants within the 20 candidate genes were extracted from exome-sequencing data of 42 subjects with EE and no previous
genetic diagnosis. We identified 7 rare non-synonymous variants in 7 of 20 genes and performed Sanger sequence validation in affected
probands and parental samples. De novo variants were found only in SLC1A2 (aka EAAT2 or GLT1) (c.244G>A [p.Gly82Arg]) and
YWHAG (aka 14-3-3g) (c.394C>T [p.Arg132Cys]), highlighting the potential cause of EE in 5% (2/42) of subjects. Seven additional
subjects with de novo variants in SLC1A2 (n ¼ 1) and YWHAG (n ¼ 6) were subsequently identified through online tools. We identified
a highly significant enrichment of de novo variants in YWHAG, establishing their role in early-onset epilepsy, and we provide additional
support for the prior assignment of SLC1A2. Hence, in silico modeling of brain co-expression is an efficient method for nominating
EE-associated genes to further elucidate the disorder’s etiology and genotype-phenotype correlations.
Developmental and epileptic encephalopathies (EEs) are a
genetically heterogeneous group of severe epilepsy syn-
dromes characterized by early-onset, treatment-resistant
seizures and developmental slowing or regression.1 There
are currently 51 established EE-associated genes, in which
many causal mutations arise de novo.2–13 However, with
the advent of high-throughput sequencing, an increasing
number of candidate genes are emerging with only a
single reported de novo variant.4,5 The interpretation of
these findings remains challenging given that on average
0.5 de novo exonic mutations are expected per individ-
ual.14–16 Co-segregation analyses in large pedigrees, which
usually provide strong genetic evidence for pathogenicity,
are not applicable in the case of de novomutations. Rather,
identification of recurrent mutations or different muta-
tions in the same gene helps provide evidence for causality.
Such candidate genes can also be prioritized in silico if they
belong to the same biological networks, including ion
channels and synaptic and regulatory pathways.
Of 179 candidate genes with a single de novo variant
reported,4 Oliver et al.17 prioritized 19 on the basis of
brain-specific co-expression with a reference gene set of
29 established EE-associated genes. Five of the 19 candi-
date genes have since been confirmed as disease causing,
demonstrating the validity of this approach. Using an
updated reference gene set of 51 established EE-associated
genes, Oliver et al.13 recently highlighted six more genes
that are co-expressed. Here, we evaluate rare coding vari-
ability in all co-expressed candidate genes (n ¼ 20) nomi-
nated by Oliver et al.13,17 in 42 EE-affected individuals
(14 males and 28 females) selected from 149 epileptic indi-
viduals hospitalized and/or attending BC Children’s
Hospital neurology, medical genetic, and biochemical
clinics and enrolled in the Epilepsy Genomics (EPGEN)
Study. Eligible subjects had a clinical diagnosis of epi-
lepsy1 with onset by the age of 5 years and an unknown
cause after appropriate investigations, including electroen-
cephalography (EEG), head MRI, neurometabolic testing,
and chromosome microarray. Seizure types and electro-
clinical syndromes were classified according to the Interna-
tional League Against Epilepsy (ILAE).1 Individuals with
self-limiting benign electroclinical syndromes, such as
childhood absence epilepsy (onset > 4 years), were
excluded on the basis of its more likely multifactorial in-
heritance. Individuals were identified to have an epileptic
encephalopathy if the epileptic activity itself was deter-
mined to or was at risk of (e.g., new onset of infantile
spasms) contributing to severe cognitive and behavioral
impairments above and beyond what might be expected
from the underlying pathology alone.1 The average age
of seizure onset for the 42 selected EE subjects was
20.6 5 18.9 months (1 week to 5 years). Focal seizures
with impaired awareness were the most common seizure
type (20 subjects [47.6%]), followed by generalized
1Centre for Applied Neurogenetics, University of British Columbia, Vancouver, BC V5R 6H8, Canada; 2Department of Neuropediatrics, Development, and
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Regional Genetics Service, St. George’s University Hospitals NHS Foundation Trust, London SW17 0QT, UK; 7Department of Medical Genetics, University
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myoclonic seizures (16 subjects [40%]). Informed consent
was obtained for all subjects in accordance with site-
specific institutional review boards.
Our cohort represents a highly selected group of individ-
uals without mutations in genes known to be associated
with epilepsy (n ¼ 545), including the 51 established EE-
associated genes. Variants within co-expressed candidate
genes (n ¼ 20; Table S1) were extracted from exome
sequencing data. On average, 96% (83%–100%) of the cod-
ing region was sequenced >10-fold (Table S1). Variant
annotation was performed with ANNOVAR,18 which inte-
grated data from a variety of public databases. Highly pene-
trant de novo mutations are not expected in healthy
individuals, and we assessed only extremely rare variants
(%1 carrier in the Exome Aggregation Consortium
[ExAC] Browser), including small indels and missense,
nonsense, and splicing changes (55 bp). Sanger
sequencing in probands and both parents (when available)
validated a total of seven non-synonymous variants in
seven different genes (Table 1). Variants in four genes,
GABBR2 (MIM: 607340), ANK3 (MIM: 600465), NBEA
(MIM: 604889), and ACOT4 (MIM: 614314), were in-
herited from unaffected parents, so pathogenicity is doubt-
ful. A variant of unknown significance was identified in
PLXNA1 (MIM: 601055); whereas the mother is not a car-
rier, paternal DNA was not available. The remaining two
mutations were de novo: (1) c.244G>A (p.Gly82Arg) in
SLC1A2 (solute carrier family 1 member 2 [MIM: 600300;
GenBank: NM_004171.3]) was identified in a 6-year-old
boy (subject A) with seizure onset at 6 weeks and (2)
c.394C>T (p.Arg132Cys) in YWHAG (tyrosine 3-monoox-
ygenase/tryptophan 5-monooxygenase activation protein
gamma, also known as 14-3-3g [MIM: 605356; GenBank:
NM_012479.3]) was identified in an 18-year-old woman
(subject B) with seizure onset at 12 months (Table 2).
In an attempt to identify additional carriers of de
novo variants in SLC1A2 and YWHAG, we queried biomed-
ical literature on PubMed and three online resources:
(1) GeneMatcher,21 a freely accessible tool that connects
clinicians and researchers with interests in the same
gene; (2) DECIPHER, which contains exome sequencing
data from nearly 4,300 families affected by developmental
disorders;22,23 and (3) AnnEX, a collaborative platform that
interrogates exomes specializing in neurologic and neuro-
degenerative disorders. We identified seven additional
probands: subject C (SLC1A2 c.866C>G [p.Pro289Arg]),
subject D (YWHAG c.44A>C [p.Glu15Ala]), AU027A with
autism (YWHAG c.148A>C [p.Lys50Gln]),20 ND27637
with Lennox-Gastaut syndrome (YWHAG c.387C>G
[p.Asp129Glu]),4 subjects E and F (YWHAG c.394C>T
[p.Arg132Cys]), and DDD4K.00159 with a neurodevelop-
mental disorder (YWHAG c.398A>C [p.Tyr133Ser])19
(Table 1). All mutations were de novo and resulted in
substitutions that involve highly conserved amino acids
and are predicted to be damaging by multiple in silico
algorithms (Combined Annotation Dependent Depletion
[CADD] and Rare Exome Variant Ensemble Learner
[REVEL]). None have been reported in public databases
(gnomAD Browser), and one mutation (YWHAG
c.394C>T) is recurrent in three subjects (B, E, and F). We
used denovolyzeR24 to evaluate the excess of de novo
mutations in YWHAG. Assuming that 6,869 individuals
were included, we observed a highly significant enrich-
ment of heterozygotes (0.2 expected versus 7 observed;
p ¼ 5.1 3 109; 30.83; Table 1). Although the number of
subjects in GeneMatcher was not defined, these results
remained significant (p ¼ 0.009) even when 100,000 indi-
viduals were included.
Table 2 summarizes the main clinical features of the
six affected individuals who have not previously been
described in the literature. All probands underwent
WES and had no other pathogenic or likely pathogenic
mutations in genes known to be associated with seizure
disorders. Detailed case reports are provided in the Supple-
mental Note.
SLC1A2 encodes the excitatory amino acid transporter
EAAT2 (also known as GLT-1), a glutamate transporter
that is primarily expressed in astrocytes and is responsible
for 95% of glutamate uptake activity in the mammalian
brain. Lethal spontaneous seizures and progressive
neuronal death due to excitotoxicity were reported in a
Slc1a2 knockout mouse model.25 Elevated extracellular
glutamate levels have also been reported in animal models
of epilepsy and epilepsy patients alike, particularly in indi-
viduals with temporal lobe epilepsy.26–29
EAAT2 p.Gly82Arg (subject A) substitutes a small hydro-
phobic and neutrally charged glycine with hydrophilic,
positively charged arginine within the cytoplasmic loop
joining the first pair of transmembrane domains (Figure 1).
The same substitution is reported in the Epi4K-EPGP data-
set in a subject with infantile spasms4 and two additional
individuals with a severe EE, and de novo variants
(EAAT2 p.Gly82Arg and p.Leu85Pro) were reported33 dur-
ing the preparation of this manuscript.
EAAT2 p.Pro289Arg (subject C) affects a highly
conserved residue in all human EAATs (EAAT1–EAAT5)
and their ancestral homolog. Pro289 leads to a hinge in
the middle of the fifth transmembrane domain (Figure 1).
Its substitution to positively charged arginine is pre-
dicted to cause a major structural change of the protein.
The homologous mutation (c.1047C>G [p.Pro290Arg])
in SLC1A3 (MIM: 600111), encoding EAAT1, has been
described in a subject with episodic ataxia, seizures,
migraine, and alternating hemiplegia (MIM: 612656).34
In addition to mediating secondary-active glutamate
uptake, EAATs also function as anion channels.35–38 The
EAAT1 p.Pro290Arg variant decelerates a conformational
change associated with Naþ binding, causing a decrease
in glutamate transport rates and a significant increase in
EAAT1-associated anion current amplitudes.39 EAAT1 and
EAAT2 have similar expression profiles (mainly expressed
in astrocytes and localized to plasmalemma), share basic
mechanisms of glutamate transport, and exhibit similar
anion conduction properties. Therefore, it is likely that
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Table 1. Rare Coding Variants
ID Genea hg19 Position rsID MAF Nucleotide Change Amino Acid Change CADD REVEL Inheritance Study
109 ACOT4 chr14: 74,059,006 rs762048021 4.09 3 106 c.343G>A p.Glu115Lys 13.3 0.100 paternal this study (n ¼ 42)
044 ANK3 chr10: 61,828,433 NA NA c.12206A>G p.Glu4069Gly 13.3 0.111 paternal this study (n ¼ 42)
015 GABBR2 chr9: 101,073,426 NA NA c.1955 A>G p.His652Arg 23.2 0.830 maternal this study (n ¼ 42)
062 NBEA chr13: 35,770,172 NA NA c.5099T>C p.Met1700Thr 13.2 0.079 paternal this study (n ¼ 42)
133 PLXNA1 chr3: 126,752,801 rs149124469 8.51 3 106 c.5632C>T p.Arg1878Trp 33.0 0.149 unknown
(not maternal)
this study (n ¼ 42)
Subject A SLC1A2 chr11: 35,336,636 NA NA c.244 G>A p.Gly82Arg 32.0 0.864 de novo this study (n ¼ 42)
Subjects B, E, and F YWHAG chr7: 75,959,244 NA NA c.394C>T p.Arg132Cys 33.0 0.791 de novo this study (n ¼ 42), DDD19
(n ¼ 4,293), GeneMatcher (NA)
Subject C SLC1A2 chr11: 35,314,059 NA NA c.866C>G p.Pro289Arg 26.9 0.911 de novo DDD19 (n ¼ 4,293)
Subject D YWHAG chr7: 75,988,082 NA NA c.44A>C p.Glu15Ala 27.2 0.417 de novo GeneMatcher (NA)
AU027A YWHAG chr7: 75,959,490 NA NA c.148A>C p.Lys50Gln 25.4 0.597 de novo De Rubeis et al.20 (n ¼ 2,270)
ND27637 YWHAG chr7: 75,959,251 NA NA c.387C>G p.Asp129Glu 26.9 0.524 de novo Epi4K4 (n ¼ 264)
DDD4K.00159 YWHAG chr7: 75,959,240 NA NA c.398A>C p.Tyr133Ser 27.1 0.911 de novo DDD19 (n ¼ 4,293)
Abbreviations are as follows: MAF, minor allele frequency from gnomAD; CADD, Combined Annotation Dependent Depletion (v.1.3); REVEL, Rare Exome Variant Ensemble Learner; NA, not available.
aGenBank accession numbers: ACOT4, NM_152331.3; ANK3, NM_001204403.1; GABBR2, NM_005458; NBEA, NM_015678.4; PLXNA1, NM_032242.3; SLC1A2, NM_004171.3; and YWHAG, NM_012479.3.
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Table 2. Clinical Features of Subjects with SLC1A2 and YWHAG Mutations
SLC1A2 YWHAG
Subject A Subject C Subject B Subject D Subject E Subject F
Genetic findings c.244G>A (p.Gly82Arg) c.866C>G (p.Pro289Arg) c.394C>T (p.Arg132Cys) c.44A>C (p.Glu15Ala) c.394C>T (p.Arg132Cys) c.394C>T (p.Arg132Cys)
Sex male male female female female female
Seizure onset 6 weeks 5 days 12 months 6 months <6 months <6 years (unknown)
Age 6 years 10 years 18 years 10 years 22 years 15 years
Diagnosis developmental and EE
(treatment resistant)
developmental and EE
(treatment resistant)
developmental and EE unclassified epilepsy unclassified or genetic
generalized epilepsy
unclassified or genetic
generalized epilepsy
Seizure type at onset focal motor (left leg, right
arm) initially without
impaired awareness
focal motor (face, eyes,
and right foot)
generalized myoclonic prolonged focal motor
seizure with fever
myoclonic absence, eyelid
myoclonia, myoclonic
Course of seizures focal motor 5 impaired
awareness evolving to
bilateral tonic-clonic
multiple seizure types generalized myoclonic,
atypical absence, GTC,
no febrile seizure
second prolonged seizure
with fever and then two
episodes of status
epilepticus associated
with regression and
hemiparesis
prolonged GTC with
fever, generalized
myoclonic, absence, GTC
persistence of absence
seizures
Ictal EEG not available, but capture
of right arm jerks and chin
twitching showed no EEG
correlate
spike-and-wave
discharges (age 7 weeks)
myoclonic jerks,
generalized spike-and-
wave discharge
not available spike-and-slow wave,
polyspike, and slow-wave
discharges
not available
Interictal EEG 2 months: paroxysmal
delta and frequent
bilateral mid-central
parietal spikes and sharp
waves, occasional right
temporal spikes; 4 years:
slow dysrhythmic
background, multifocal
epileptiform discharges
very high amplitude
(>500 mV), 0.7–3.3 Hz
delta and very slow waves
with intermixed
generalized sharp waves
(age 8 months)
2 years: dysrhythmic
background, generalized
atypical spike wave,
frequent bifrontal spikes;
14 years: dysrhythmic
background, rare sharp
waves in bianterior
quadrants
not available 21 months: generalized
3 Hz spike wave with
absence seizures; 10 years:
generalized polyspike
wave with myoclonic
seizures; 14 years:
occasional spike wave
8 years: bilateral
frontotemporal spikes,
generalized spike waves
Timing of seizure
occurrence
diurnal or nocturnal not provided diurnal not provided frequently early morning not provided
Head circumference 45.1 cm at 8 months
(50%), 52 cm at 5 years
(50th percentile)
44 cm at 4 months (91st
percentile)
normal þ1 SD
(mother has
macrocephaly)
53.7 cm at 15 years (20th
percentile)
normal (50th percentile)
Neurologic findings visually inattentive with
sluggish pupils, axial
hypotonia, mild limb
spasticity, dyskinetic
movements of arms
hypotonia with up-going
plantars and severe
thoraco-lumbar
kyphoscoliosis
action tremor in upper
extremities and mild
coordination difficulties
hypotonia, joint
hyperlaxity
ataxia, thoracolumbar
scoliosis
thoracolumbar
kyphoscoliosis
(Continued on next page)
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Table 2. Continued
SLC1A2 YWHAG
Subject A Subject C Subject B Subject D Subject E Subject F
Response to treatment partial response to
phenobarbital,
levetiracetam, and
clobazam;
longest seizure-free period
was 16 months
partial response to
ketogenic diet and
phenytoin, no response to
other antiseizure
medications
responded to clonazepam,
which was stopped at
8 years; lamotrigine at
10 years was ineffective
for atypical absence and
GTC seizure; seizure free
since 11 years on
divalproex sodium and
ethosuximide;
ethosuximide was weaned
off by 17 years
epilepsy under control
with divalproex sodium
partial response to
divalproex sodium and
stiripentol
epilepsy under control
with divalproex sodium
and lamotrigine
ID yes (profound) yes (severe) mild to moderate ID yes (IQ ca. 55) yes (moderate to severe) WPPSI III (6 years),
VIQ 73, PIQ 58
Development delayed (severe),
nonverbal, unable to sit
unsupported
yes (severe) early language delay, fine
motor difficulties with
tremor, ADHD
delayed delayed mildly delayed
Brain MRI 6 weeks: normal; 2 years:
incomplete myelination,
generalized atrophy, thin
corpus callosum,
abnormal signal in
thalami, putamen, and
caudate, and abnormal
peritrigonal white-matter
signal; 4 years: progressive
generalized atrophy,
persistent abnormal
signal in basal ganglia and
thalami, and
periventricular white-
matter signal
abnormalities
2 months: normal; 2.5
years: severely delayed
myelination, cerebral
atrophy, and bilateral T2
prolongation in caudate
heads and putamina
3 years: asymmetric
brainstem not thought to
be significant
generalized atrophy with
diffuse loss of white
matter
10 years: normal normal
Abbreviations are as follows: ADHG, attention-deficit hyperactivity disorder; EE, epileptic encephalopathy; EEG, electroencephalography; GTC, generalized tonic-clonic; ID, intellectual disability; PIQ, performance IQ; VIQ,
verbal IQ; WPPSI, Wechsler Preschool and Primary Scale of Intelligence.
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Figure 1. De Novo SLC1A2 and YWHAG Mutations in Individuals with Early-Onset Epilepsy
(A) Top: transmembrane topology of EAAT2 (adapted from Yernool et al.30) and localization of the variants identified in this study
(green) or previously reported (black) (the asterisk indicates a recurrent variant). Bottom: partial sequence alignment of EAAT2 orthologs
and different human EAAT proteins surrounding p.Pro289Arg (indicated by an arrow). Identical residues across all proteins are shown in
black, and residues identical to the human EAAT2 are in gray. GenBank accession numbers are as follows: Homo sapiens, NP_004162.2;
Macaca mulatta, NP_001248598.1;Mus musculus, NP_001070982.1;Gallus gallus, NP_001012917.1; Xenopus tropicalis, XP_002937340.1;
Dario rerio, NP_956273.1; Caenorhabditis elegans, NP_001024393.1; human EAAT1, NP_004163.3; human EAAT3, NP_004161.4; human
EAAT4, NP_005062.1; and human EAAT5, NP_006662.3.
(B) Top: crystal structure of 14-3-3g (PDB: 5D3E). Left: dimeric 14-3-3g is shown as green ribbons, and the phosphopeptide ligand is
shown as an orange stick. Right: close-up view of the binding groove, side chains of the residues crucial for the phosphopeptide binding,
(legend continued on next page)
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the EAAT2 p.Pro289Arg variant would have an effect
similar to that of the homologous mutation.33 Similar to
three previously reported individuals with SLC1A2 muta-
tions, our subjects have a severe phenotype consisting
of early-onset epilepsy and severe development delay.
Four of five individuals have multiple seizure types, but
subject A (who has the same mutation as the subject
reported to have infantile spasms)4 primarily has focal mo-
tor seizures. This subject also experienced regression with
an episode of lethargy and irritability, whereas no definite
regression occurred in the other subjects. Neuroimaging
revealed brain atrophy and abnormalities in white
matter and basal ganglia in subjects A and C (Figure 2).
The atrophy is possibly due in part to glutamate-induced
excitotoxicity.25
Moreover, we identified four subjects (B and D–F) with
de novo variants in YWHAG. The 14-3-3 family has seven
conserved isoforms that are highly expressed in the
mammalian brain. They are involved in a wide variety of
biological processes, including intracellular signaling,
cell-cycle control, apoptosis, and protein trafficking.40
Knockdown of 14-3-3g in zebrafish resulted in delayed
brain development, reduced brain size, and increased
diameter of the heart tube.41 Curiously, in mice, a decrease
or increase in 14-3-3g leads to delayed neuronal migration
of pyramidal neurons in the cerebral cortex.42,43 Hence,
normal neuronal migration in the developing brain is
exquisitely sensitive to 14-3-3g levels. Atypical neuronal
migration has previously been implicated in epilepsy.
Haploinsufficiency of YWHAG has been proposed as a
potential cause of infantile spasms in individuals with
Williams-Beuren syndrome (WBS [MIM: 194050]),41 a
multisystem developmental disorder caused by a recurrent
de novo hemizygous deletion of 1.5 Mb in chromosomal
region 7q11.23.44,45 Atypical distal 7q11.23 deletions
ranging in size from 180 kb to 19.6 Mb have been
described in several individuals presenting with a more
severe phenotype that includes developmental delay,
autistic features, and epilepsy. Three genes—MAGI2
(MIM: 606382), HIP1 (MIM: 601767), and YWHAG—
have been suggested as possible candidates for these
atypical features.46–53 Ramocki et al.51 suggested that hap-
loinsufficiency of HIP1 is sufficient to alter neuronal
homeostasis and cause focal and generalized epilepsies
and cognitive dysfunction. However, their findings do
not exclude the possibility that YWHAG loss of function
is sufficient to cause neurological phenotypes alone, as
proven by our results. Epilepsy and infantile spasms were
also described in WBS individuals harboring typical
7q11.23 deletions,54 albeit in relatively few subjects.55
Moreover, a recent paper56 described a subject harboring
a WBS-typical 1.41 Mb deletion and presenting with
additional infantile-onset refractory EE and severe devel-
opmental delay caused by a second, independent de
novomutation inGABRA1 (MIM: 137160). Hence, atypical
aspects seen in individuals with a typical 7q11.23 deletion
might also be caused by a second co-occurring but unre-
lated genetic defect.
Subject D harbors a de novo 14-3-3g p.Glu15Ala variant.
Native 14-3-3 exists in monomeric and dimeric states as
homo- and heterodimers, respectively, although 14-3-3g
is almost entirely dimeric.57 Glu15 is part of a triad of res-
idues (Leu13, Ala14, and Glu15) necessary for 14-3-3g
dimerization,58,59 and its ability to complex with other
proteins is potentially inhibited by substitution at this site.
The same recurrent de novo 14-3-3g p.Arg132Cys
variant was identified in subjects B, E, and F. The arginine
residue at position 132 is part of a highly conserved triad of
two arginines and a tyrosine (Arg132-Arg57-Tyr133)
(Figure 1) that normally form a positively charged pocket
within a binding groove for interacting phosphopepti-
des.57,60 An individual (ND27637) with Lennox-Gastaut
syndrome and a de novo p.Asp129Glu variant is present
in the Epi4K-EPGP dataset.4 The Asp129 residue is also
located within the 14-3-3g binding groove (Figure 1) and
plays an important role in determining the orientation of
the phosphorylated peptides.57 A de novo mutation
affecting position p.Tyr133Ser has been reported in a
Deciphering Developmental Disorders cohort individual
(DDD4K.00159) severely affected by a neurodevelopmen-
tal disorder,19 but we were unable to contact the clinician
who followed this subject. Finally, a p.Lys50Gln de novo
variant was identified in a subject with autism
(AU027A).20 The Lys50 residue is located on the charged
face of the binding groove (together with Arg57, Arg61,
Arg132, and Tyr133) (Figure 1) and is essential for ligand
binding.61–63
All four subjects (B and D–F) from this study are females
with seizure onset in the first year of life, although a precise
age of onset for subject F is unknown. Subjects B, E, and
F have the same mutation and similar epilepsy phenotype,
which includes generalized epilepsy with myoclonic,
(atypical) absence, and generalized tonic-clonic (GTC)
seizures. Subject E also has prolonged GTC seizures and
and hydrogen bonds (green dashed lines). Images were generated with Swiss-Pdb Viewer v.4.10.31 Bottom: partial sequence alignment of
14-3-3g orthologs and different human 14-3-3 proteins surrounding the mutated residues identified in this study (green) or previously
reported (black). Identical residues across all proteins are shown in black, and residues identical to the human 14-3-3g are in gray.
GenBank accession numbers are as follows: Homo sapiens, NP_036611.2; Macaca mulatta, NP_001181365.1; Mus musculus,
NP_061359.2; Gallus gallus, NP_001026648.1; Xenopus tropicalis, NP_001072309.1; Dario rerio, NP_998187.1; Caenorhabditis elegans,
AAA61872.1; human 14-3-3b, NP_003395.1; human 14-3-3ε, NP_006752.1; human 14-3-3 z, NP_001129174.1; human 14-3-3 h,
NP_003396.1; human 14-3-3 q, NP_006817.1; and human 14-3-3 NP_006133.1.
Sequences were aligned with CLUSTAL Omega.32 Asterisks indicate positions with a single fully conserved residue, colons indicate
conservation between groups with strongly similar properties, and periods indicate conservation between groups with weakly similar
properties.
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fever. Subject D’s epilepsy is characterized by episodes of
status epilepticus with or without fever. However, no sub-
ject had infantile spasms, which have been reported in
some WBS individuals with atypical deletions encompass-
ing YWHAG. Themajority (three of four) have experienced
seizure control on medication. All individuals have devel-
opmental delay with intellectual disability, and subject
E was also diagnosed with autism spectrum disorder. Sub-
jects B and E have tremor, coordination difficulties, or
ataxia, and subjects E and F have scoliosis. Neuroimaging
was unremarkable in subjects B, E, and F. The different
and less severe clinical presentation of subject D might
be explained by a partially different molecular mechanism
associated with her specificmutation. Impairment of phos-
phopeptide binding is only a secondary consequence of
impaired protein dimerization.
Empirically, we have demonstrated the validity of
brain-specific co-expression for prioritizing EE candidate
genes.13,17 We have identified likely pathogenic muta-
tions in 2 of 20 genes, which enabled us to make a
genetic diagnosis in 5% (2/42) of our subjects. However,
we do not rule out that mutations in the remaining
18 candidate genes have a role in EE, because more indi-
viduals must still be assessed. With the identification of
both known and previously unreported mutations, our
study provides further evidence for SLC1A2 mutations
in EE and suggests a gain-of-function mechanism for
this rather severe presentation. Furthermore, our data
indicate that YWHAG de novo mutations cause early-
onset epilepsy, including EE and intellectual disability,
and provide the rationale for therapeutic development
to enhance 14-3-3g dimerization and/or ligand binding.
All identified de novo mutations are predicted to impair
dimerization and phosphopeptide binding and were ulti-
mately found in seven unrelated subjects, three of whom
present with similar epilepsy phenotypes. Nevertheless,
Figure 2. MRI Findings in Individuals with SLC1A2Mutations
(A–G) Subject A. Sagittal T1 (A) and axial T2 (B) at 6 weeks revealed a thin corpus callosum but within normal limits for age. Axial T2
(C and D) and sagittal T1 (E) at 2 years revealed volume loss and a thin corpus callosum, increased T2 white-matter signal intensity, de-
layed myelination, decreased T2 signal of thalami, and increased T2 signal of putamen and caudate. At 4 years, axial T2 (F) and sagittal
T1 (G) showed progressive volume loss; persistent abnormal signal in thalami, putamen, and caudate; a focal area of increased T2 signal
in the left lentiform nucleus; and a thin corpus callosum.
(H–J) Subject C. Axial T2 (H) and sagittal T1 (I) at 2 months were normal. At 2.5 years, axial T2 (J) revealed atrophy, delayedmyelination,
and bilateral T2 prolongation in caudate heads and putamina.
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it is important to consider both developmental and
epileptic components, especially in YWHAG encephalop-
athy, given protein function and the observed pheno-
typic heterogeneity.
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